NBI-1065845 added to medication for major depression
About this title
Read the official source — NCT06786624This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- Little Rock and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 200
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT06786624
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Recruitment & locations
Little Rock · Garden Grove · Orange
15 more locations
- Pico Rivera
- San Diego
- Upland
- Hollywood
- Maitland
- Boston
- Watertown
- Mount Kisco
- Avon Lake
- Westlake
- Dallas
- Houston
- Richmond
- The Woodlands
- Everett
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1065845 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
